Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder

被引:4
作者
Sun, Houliang [1 ]
Cui, Shilei [1 ]
Gao, Fei [1 ]
You, Qisheng [2 ]
Li, Yong [3 ]
Wang, Jiawei [1 ]
Zhang, Xiaojun [1 ]
机构
[1] Capital Med Univ, Beijing Tongren Hosp, Dept Neurol, 1 Dong Jiao Min Xiang, Beijing 100730, Peoples R China
[2] Capital Med Univ, Beijing Tongren Hosp, Ophthalmol Ctr, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Tongren Hosp, Dept Radiol, Beijing, Peoples R China
关键词
Neuromyelitis optica spectrum disorder; Eye movement; Saccade; Visual handicap; MULTIPLE-SCLEROSIS; DIAGNOSTIC-CRITERIA; BRAIN-STEM; MANIFESTATIONS; DISTINCTION; ANTIBODY; MS;
D O I
10.1016/j.jns.2017.11.033
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purpose: Neuromyelitis optica spectrum disorder (NMOSD) has been recognized as a disease characterized by severe visual afferent impairment. Abnormal eye movements, as the other important neuroophthalmic manifestation of NMOSD, were commonly overlooked. The aim of our study was to describe the ocular motor manifestations of AQP4-IgG positive NMOSD patients, and explore the value of eye movement abnormalities in the evaluation of the disabled disease. Methods: Systemic clinical bedside ocular motor examinations and quantitative horizontal saccadic eye movement assessments were performed in 90 patients with AQP4-IgG positive NMOSD. General disability was evaluated by expanded disability status scale (EDSS). Vision-specific functional status was evaluated by the National Eye Institute-Visual Function Questionnaire (NEI-VFQ 25) and the 10-item neuro-ophthalmic supplement. Brain magnetic resonance imaging (MRI) was acquired in all patients. Results: In clinical examination, eye movement abnormalities were found in 38% of NMOSD patients. Abnormalities in the quantitative saccadic test were found in 67% of NMOSD patients, including 48% of patients with clinically normal eye movements. EDSS scores in patients with clinical eye movement abnormality were significantly higher (P < 0.001) than those with a normal examination. The 10-item neuro-ophthalmic supplement score was significantly associated with quantitative saccadic eye movement abnormalities (P = 0.031). Conclusions: Eye movement abnormalities were common in AQP4-IgG positive NMOSD patients, and were associated with general disability and specific visual handicap. The systemic clinical eye movement examination combined with the quantitative saccade test was easy to perform, and could provide additional useful information in evaluating NMOSD.
引用
收藏
页码:91 / 95
页数:5
相关论文
共 50 条
  • [41] Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study
    Pittock, Sean J.
    Lennon, Vanda A.
    McKeon, Andrew
    Mandrekar, Jay
    Weinshenker, Brian G.
    Lucchinetti, Claudia F.
    O'Toole, Orna
    Wingerchuk, Dean M.
    LANCET NEUROLOGY, 2013, 12 (06) : 554 - 562
  • [42] Predictors for acute respiratory failure in AQP4-IgG-positive neuromyelitis optica spectrum disorders patients with medullary lesions
    Zhou, Jing
    Lu, Yaxin
    Shen, Shishi
    Fang, Ling
    Chen, Chen
    Wang, Xia
    Li, Cong
    Liu, Zifeng
    Zhou, Hongyu
    Quan, Chao
    Qiu, Wei
    Zhong, Xiaonan
    JOURNAL OF CLINICAL NEUROSCIENCE, 2023, 114 : 131 - 136
  • [43] MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis
    Clarke, Laura
    Arnett, Simon
    Bukhari, Wajih
    Khalilidehkordi, Elham
    Sanchez, Sofia Jimenez
    O'Gorman, Cullen
    Sun, Jing
    Prain, Kerri M.
    Woodhall, Mark
    Silvestrini, Roger
    Bundell, Christine S.
    Abernethy, David A.
    Bhuta, Sandeep
    Blum, Stefan
    Boggild, Mike
    Boundy, Karyn
    Brew, Bruce J.
    Brownlee, Wallace
    Butzkueven, Helmut
    Carroll, William M.
    Chen, Cella
    Coulthard, Alan
    Dale, Russell C.
    Das, Chandi
    Fabis-Pedrini, Marzena J.
    Gillis, David
    Hawke, Simon
    Heard, Robert
    Henderson, Andrew P. D.
    Heshmat, Saman
    Hodgkinson, Suzanne
    Kilpatrick, Trevor J.
    King, John
    Kneebone, Christopher
    Kornberg, Andrew J.
    Lechner-Scott, Jeannette
    Lin, Ming-Wei
    Lynch, Christopher
    Macdonell, Richard A. L.
    Mason, Deborah F.
    McCombe, Pamela A.
    Pereira, Jennifer
    Pollard, John D.
    Ramanathan, Sudarshini
    Reddel, Stephen W.
    Shaw, Cameron P.
    Spies, Judith M.
    Stankovich, James
    Sutton, Ian
    Vucic, Steve
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [44] Paraneoplastic AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder Associated With Teratoma A Case Report and Literature Review
    Ikeguchi, Ryotaro
    Shimizu, Yuko
    Shimomura, Ayato
    Suzuki, Miki
    Shimoji, Kanoko
    Motohashi, Takashi
    Yamamoto, Tomoko
    Shibata, Noriyuki
    Kitagawa, Kazuo
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (05):
  • [45] Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder
    Liu, Chunxin
    Xiao, Hui
    Zhang, Xiayin
    Zhao, Yipeng
    Li, Rui
    Zhong, Xiaonan
    Wang, Yuge
    Shu, Yaqing
    Chang, Yanyu
    Wang, Jingqi
    Li, Caixia
    Lin, Haotian
    Qiu, Wei
    BRAIN AND BEHAVIOR, 2021, 11 (05):
  • [46] Frequency of brain MRI abnormalities in neuromyelitis optica spectrum disorder at presentation: A cohort of Latin American patients
    Carnero Contentti, Edgar
    Marques, Vanessa Daccach
    Soto de Castillo, Ibis
    Tkachuk, Veronica
    Barreira, Amilton Antunes
    Armas, Elizabeth
    Chiganer, Edson
    Cruz, Camila de Aquino
    Luis Di Pace, Jose
    Pablo Hryb, Javier
    Lavigne Moreira, Carolina
    Lessa, Carmen
    Molina, Omaira
    Perassolo, Monica
    Soto, Arnoldo
    Caride, Alejandro
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 19 : 73 - 78
  • [47] ABCB1 gene polymorphisms impact the effect of high-dose intravenous methylprednisolone therapy on optic neuritis associated with AQP4-IgG-positive neuromyelitis optica spectrum disorder
    Dai, Yuyang
    Ni, Siyang
    Wu, Feng
    Guo, Shaojie
    Zhao, Xiuli
    Wang, Jiawei
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (09) : 1379 - 1387
  • [48] Satralizumab in the treatment of neuromyelitis optica spectrum disorder
    Duchow, Ankelien
    Bellmann-Strobl, Judith
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (01) : 49 - 59
  • [49] Frequency of comorbidities in Neuromyelitis Optica spectrum disorder
    Barzegar, Mahdi
    Mirmosayyeb, Omid
    Nehzat, Nasim
    Vaheb, Saeed
    Shaygannejad, Vahid
    Asgari, Nasrin
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 48
  • [50] Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region
    Dale, G. H.
    Svendsen, K. B.
    Gjelstrup, M. C.
    Christensen, T.
    Houen, G.
    Nielsen, E.
    Bek, T.
    Petersen, T.
    ACTA NEUROLOGICA SCANDINAVICA, 2018, 137 (06): : 582 - 588